Archived
This content is available here strictly for research, reference, and/or recordkeeping and as such it may not be fully accessible. If you work or study at University of Kentucky and would like to request an accessible version, please use the SensusAccess Document Converter.
Abstract
Sepsis remains a significant medical problem. TNFα is a central cytokine in sepsis pathophysiology. We conducted a phase IIa trial in patients with severe sepsis to assess the safety and tolerability of an intravenously infused ovine-derived polyclonal anti-TNFα Fab fragment (AZD9773).
Document Type
Presentation
Publication Date
3-11-2011
Digital Object Identifier (DOI)
http://dx.doi.org/10.1186/cc9683
Repository Citation
Morris, Peter E.; Zeno, Brian; Bernard, Andrew C.; Huang, Xiangning; Simonson, Steven G.; and Bernard, Gordon R., "Safety and tolerability of an ovine-derived polyclonal anti-TNFα Fab fragment (AZD9773) in patients with severe sepsis" (2011). Surgery Presentations. 1.
https://uknowledge.uky.edu/surgery_present/1
Notes/Citation Information
Published in Critical Care, v. 15 (Suppl. 1): P263.
© 2011 Morris et al.
From the 31st International Symposium on Intensive Care and Emergency Medicine (Brussels, Belgium: 22-25 March 2011).